Company Shares of BioScrip Drops by -12.72%

BioScrip (NASDAQ:BIOS) has tumbled 12.72% during the past week and has dropped 0.4% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 11.67%. BioScrip (NASDAQ:BIOS) has underperformed the index by 1.31% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

BioScrip (NASDAQ:BIOS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.25 and $2.23 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.59. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.47, notching a gain of 19.32% for the day. The total traded volume was 11,155,509 . The stock had closed at $2.07 on the previous day.

The company shares have dropped -35.68% from its 1 Year high price. On Jun 29, 2015, the shares registered one year high at $3.93 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $2.60 and the 200 Day Moving Average price is recorded at $2.13.

On the companys insider trading activities, Golding David W, director of Bioscrip, Inc., had purchased 20,000 shares on August 18, 2015. The total value of the transaction was $30,800. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Currently the company Insiders own 4.7% of BioScrip shares according to the proxy statements. Institutional Investors own 86.39% of BioScrip shares.

BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.

Leave a Reply

Janet Gordon - Is it time to Sell?

Top Brokerage Firms are advising their investors on Janet Gordon. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.